

IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Ales Fanc et al.

Application No.: 10/575,986

Filed: April 17, 2006

For: METHOD OF PRODUCING DOSAGE
UNITS OF A SOLID DRUG FORM
CONTAINING WARFARIN SODIUM
SALT AS ACTIVE COMPONENT



Group Art Unit: Unassigned

Examiner: Unassigned

Confirmation No.: Unassigned

FIRST INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

The documents are being submitted within three (3) months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later. Since these documents are being filed within the time period set forth in 37 C.F.R. § 1.97(b), no fee or statement is required.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BUCHANAN INGERSOLL & ROONEY PC

Date: July 19, 2006

By:

Benton S. Duffett, Jr.

Registration No. 22030


P.O. Box 1404
Alexandria, VA 22313-1404
703 836 6620

**FIRST
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Application 10/575,986
 Filing Date April 17, 2006
 First Named Inventor Ales FRANC et al.
 Examiner Name Unassigned
 Attorney Docket No. 1034433-000008



U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)
	2003/0211071	A1	Bologna et al.	11-13-2005

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	STATUS						
					Translation	Partial Translation	Eng. Lang. Summary	Search Report	IPER	Abstract	Cited in Spec
	WO 01/78681	A1	WIPO	10-25-2001						X	
	WO 00/00179	A1	WIPO	01-06-2000							
	WO 91/04031	A1	WIPO	04-04-1991							
	WO 2005/112900	A1	WIPO	12-01-2005							
	JP 2005-263790		JAPAN	09-29-2005						X	
	WO 2005/06539	A2	WIPO	7-21-2005							
	WO 2004/066910	A2	WIPO	08-12-2004							
	WO 03/004009	A1	WIPO	01-16-2003							

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Ales Fanc et al.

Application No.: 10/575,986

Filing Date: April 17, 2006

Title: METHOD OF PRODUCING DOSAGE
UNITS OF A SOLID DRUG FORM
CONTAINING WARFARIN SODIUM
SALT AS ACTIVE COMPONENT



Group Art Unit: Unassigned

Examiner: Unassigned

Confirmation No.: Unassigned

INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed is a 1.97 or 1.98 Information Disclosure Statement (IDS) and
accompanying form PTO-1449 for the above-identified patent application.

- ☒ No additional fee for submission of an IDS is required.
- ☐ The fee of 180 as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e), and the fee of 180 as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge _____ to Deposit Account No. 02-4800 for the fee due.
- ☐ A check in the amount of _____ is enclosed for the fee due.
- ☐ Charge _____ to credit card for the fee due. Form PTO-2038 is attached.
- ☒ The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BUCHANAN INGERSOLL & ROONEY PC

Date July 19 2006

By:

Benton S. Duffett, Jr.
Registration No. 22030

P.O. Box 1404
Alexandria, VA 22313-1404
703 836 6620